Stifel Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating, Cuts Target Price to $1
Stifel Nicolaus Reaffirms Their Hold Rating on VistaGen Therapeutics (VTGN)
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Ultragenyx Pharmaceutical (RARE)
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating
Vistagen Therapeutics Cut to Market Perform From Outperform by William Blair
Vistagen Therapeutics Analyst Ratings
Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9
Vistagen Downgraded to Hold From Buy at Jefferies
William Blair Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating
Maxim Group Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating
Vistagen Downgraded to Hold From Buy at Stifel
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating
VistaGen Therapeutics: Buy Rating Affirmed Amid Promising Fasedienol Trials and Market Potential
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Analysts Predict Up to 550% Rally for These 2 'Strong Buy' Penny Stocks
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating
